SAN DIEGO, CA–(Marketwire – Sep 20, 2011) – True Diagnostics, Inc.T (www.TrueDiagnostics.com) announces the Company has received sFDA clearance for its TrueDXT Platform with its first test for TSH and expects shipments to China to begin before the end of the year. The TrueDX Platform produces quantitative results using LFIA (Lateral Flow Immunoassay) technology and measures the severity of conditions, produces results in minutes from a finger prick of blood (or small urine or saliva sample), and is portable. This allows point-of-care professionals to begin patient treatment immediately. With the TrueDX Platform, the Company can effectively take any biomarker, quickly commercialize it to produce quantitative results, and bring it to market.
Jerry Lee, President/CEO, stated, “After years of development, we broke the code on producing quantitative results in minutes on an LFIA platform which can handle boundless applications. We also expect to make an announcement soon concerning a significant distribution partnership which clarifies how we are entering the China market with our new TrueDX Platform with TSH tests.”
About the Company
True Diagnostics, Inc. creates diagnostic solutions for the $18 billion point-of-care IVD market. After 30 years in the global medical diagnostic field, the inventor of the pregnancy test created the TrueDX Platform which can measure the severity of any medical condition (using only a finger prick of blood, small urine or saliva sample, toxins, surface bacteria, and more), provide results in minutes (not days), and is portable. The TrueDX Platform takes point-of-care, point-of-incidence, and remote-of-care applications out of the lab to allow patient treatment to begin immediately. The flexibility of the TrueDX Platform creates unique and powerful opportunities for new diagnostic solutions through its ability to: 1) quickly bring new diagnostic tests to market; and, 2) open new geographic and application markets.
For more information, call 760-683-9158 or go to www.TrueDiagnostics.com